{"name":"Tasly Biopharmaceuticals Co., Ltd.","slug":"tasly-biopharmaceuticals-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Recombinant human urokinase","genericName":"Recombinant human urokinase","slug":"recombinant-human-urokinase","indication":"Pulmonary embolism","status":"phase_3"},{"name":"rhPro-UK simulation agent","genericName":"rhPro-UK simulation agent","slug":"rhpro-uk-simulation-agent","indication":"Acute ischemic stroke","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"rhPro-UK","genericName":"rhPro-UK","slug":"rhpro-uk","indication":"Treatment of solid tumors","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Aspirin simulation agent","genericName":"Aspirin simulation agent","slug":"aspirin-simulation-agent","indication":"Cardiovascular disease prevention or treatment (specific indication unclear from available information)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"B1962","genericName":"B1962","slug":"b1962","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"Recombinant human urokinase","genericName":"Recombinant human urokinase","slug":"recombinant-human-urokinase","phase":"phase_3","mechanism":"Recombinant human urokinase is a thrombolytic agent that works by activating plasminogen to plasmin, which then breaks down blood clots.","indications":["Pulmonary embolism","Ischemic stroke"],"catalyst":""},{"name":"rhPro-UK","genericName":"rhPro-UK","slug":"rhpro-uk","phase":"phase_3","mechanism":"rhPro-UK is a recombinant human prokineticin-2 analogue that acts as a prokineticin-2 receptor agonist.","indications":["Treatment of solid tumors"],"catalyst":""},{"name":"rhPro-UK simulation agent","genericName":"rhPro-UK simulation agent","slug":"rhpro-uk-simulation-agent","phase":"phase_3","mechanism":"rhPro-UK is a recombinant human prourokinase that converts plasminogen to plasmin to dissolve blood clots.","indications":["Acute ischemic stroke","Acute myocardial infarction","Pulmonary embolism"],"catalyst":""},{"name":"Aspirin simulation agent","genericName":"Aspirin simulation agent","slug":"aspirin-simulation-agent","phase":"phase_3","mechanism":"An aspirin simulation agent mimics the antiplatelet and anti-inflammatory effects of aspirin through a novel mechanism or formulation approach.","indications":["Cardiovascular disease prevention or treatment (specific indication unclear from available information)"],"catalyst":""},{"name":"B1962","genericName":"B1962","slug":"b1962","phase":"phase_2","mechanism":"B1962 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxNYk5fUTdiZXJyZXNiS3ZQc1ZYRldqQ1BKQ2tEcVdqRlZ1U0o2dzNLSEwyU2o3czBDVnpKWC1aYnFJMVNUZ0hDZFRpS2trZGpzUGRJcXltYXoxYWdaLXhzems0VG1ObS1sRzdmUmJ1OFpnSHVwcXpCQXlvdVcxcjJOTWlVTHllcFZRWWItWGJneXI3cGdVb3lXS0RRRktkS0xYMGNqcTY2eXRWTHBTM0NrTGJvRjN6a2ctZWlKTzQyZFZMNWlTWDU1SzZINjh4bVdOVkUxMHhhSjAzX2QxZWMxUDM3MUxSbXVmdkJ2aFhZWGRKbU5IR19kVTN2WVJOSTZkOHpRWWdoVnFFTnNhaGc?oc=5","date":"2026-04-07","type":"trial","source":"Barchart.com","summary":"Hepatitis B Virus Infection Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com","headline":"Hepatitis B Virus Infection Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Trea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOX2xMdVlLZXJlQjY4bWVCQnBoWGdoa0JPNE1mVG5KbjNuYTZabnJoVG9yWnRaU1RRM2tMZGFHMEF1Z0NuMXpqa3hfNUtXelNaWXNtOW9WSWt1cU02RXlVemwtR2JVVEVjcTUtNVR6aXlsM3ByU0hjUktBeUtiS1hGV0FOY2VrY3Z2VXlHVHZLOUxoMjlSYWU4TjRNX2JrOTBBSjFfeUE5Z0wxcEV3SDZZZ1J2N0JwRzZubTJ0SklzbFlWVThhbC16ZFVUT2J6UTRySmxmSnRwVQ?oc=5","date":"2025-03-05","type":"pipeline","source":"prnewswire.com","summary":"Global Interferons Market is Predicted to Reach ~USD 14 Billion by 2032 | DelveInsight - prnewswire.com","headline":"Global Interferons Market is Predicted to Reach ~USD 14 Billion by 2032 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQcEEzSW1zcWZLUXBPN2tYVUM3N1RjOUJEam1EYnZzQjN4eThvU3JVLUNEcFV5RURCX2Q2R0lidG5Tb1dVQjBpUWVUczh6UU1nUV9MX1F4UjVWZ2ZjR19Va3NZOXR2d3dQM21kT1pTdHpBa2VmaTdsQTB6d25acnlOekx1aVprRzhNVHdnUi1TZWp2cVdxdk95YjNLRGc2Ym1E?oc=5","date":"2019-06-26","type":"pipeline","source":"NAI500","summary":"Tasly Biopharma Files for Hong Kong IPO That Could Raise $1 Billion - NAI500","headline":"Tasly Biopharma Files for Hong Kong IPO That Could Raise $1 Billion - NAI500","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE0wR1ViZ0Z4OHpfOEU2UVJWX0o2UUlzZjFxV0E1OEVvZzItVVRTR1hXME9TNmx3QkVBUjM5UlhNNG1zVFVHaDBNU2tLYkFCdWU5YnhHX2pEeTNKR1dIV0JzQi10WmYyOU5RSXF0cGU1X0VOV28?oc=5","date":"2015-08-19","type":"pipeline","source":"China Daily","summary":"Getting TCM accepted in US - China Daily","headline":"Getting TCM accepted in US","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":4,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}